Nxera Pharma and Cancer Research UK have initiated a Phase 2a clinical trial for the drug HTL0039732, a novel EP4 antagonist, to treat advanced solid tumors. The trial follows successful Phase 1 results, showing safe doses and early efficacy in combination with atezolizumab. The drug targets EP4 to enhance the immune system’s ability to detect and control cancer cells. The trial will focus on patients with resistant or refractory tumors, with recruitment ongoing at various sites. Nxera Pharma is optimistic about the potential of HTL0039732 in treating difficult-to-treat cancers, and further updates will be shared as the trial progresses.

Read more at GlobeNewswire: Nxera Pharma and Cancer Research UK Announce First Patient